Mechanisms of Drug-Induced Proteostasis Collapse

Abstract

Drug-induced proteostasis collapse is a crucial yet often underappreciated complication in clinical medicine, affecting cellular protein quality control systems and leading to a spectrum of disorders. This review explores the epidemiology, pathophysiological mechanisms, risk factors, clinical manifestations, diagnostic strategies, and management approaches for drug-induced proteostasis collapse, drawing from recent PubMed-indexed studies and clinical guidelines. Emphasis is placed on underlying molecular mechanisms, practical clinical implications, and emerging therapeutic strategies relevant to physicians, pharmacists, and other healthcare professionals.

Introduction

The concept of proteostasis, or protein homeostasis, encompasses the dynamic regulation of the cellular proteome through coordinated processes of protein synthesis, folding, trafficking, and degradation. Disruption of proteostasis is implicated in the pathogenesis of various diseases, including neurodegeneration, metabolic syndromes, and cancer. Drug-induced proteostasis collapse refers to pharmacologically triggered disturbances in these regulatory networks, often resulting in the accumulation of misfolded or aggregated proteins, cellular stress, and subsequent tissue injury. Understanding the mechanisms underlying this phenomenon is critical for optimizing pharmacotherapy, minimizing adverse effects, and improving patient outcomes.

Epidemiology / Disease Burden

The true incidence of drug-induced proteostasis collapse is likely underestimated due to challenges in diagnosis and the overlap with primary disease pathology. Reported cases are most prevalent with chemotherapeutic agents, proteasome inhibitors, immunosuppressants, and certain antibiotics. Neurodegenerative complications secondary to drug-induced protein aggregation, such as Parkinsonian syndromes following antipsychotic use or chemotherapy-induced peripheral neuropathy, highlight the clinical burden. The disease burden is amplified in populations with existing proteostatic vulnerabilities, such as the elderly or those with genetic predispositions, underscoring the need for heightened clinical vigilance.

Pathophysiology

Proteostasis collapse occurs when the capacity of cellular quality control systems namely, molecular chaperones, the ubiquitin-proteasome system (UPS), and autophagy becomes overwhelmed or inhibited. Drugs may induce collapse by directly impairing chaperone function (e.g., geldanamycin inhibiting HSP90), inhibiting proteasomal degradation (e.g., bortezomib), or disrupting autophagic flux (e.g., chloroquine). These disruptions lead to the accumulation of misfolded or damaged proteins, endoplasmic reticulum (ER) stress, activation of the unfolded protein response (UPR), and, ultimately, apoptotic or necrotic cell death. Chronic proteostatic stress can also trigger inflammatory cascades, contributing to organ dysfunction and disease progression.

Risk Factors

Risk factors for drug-induced proteostasis collapse include advanced age, pre-existing neurodegenerative or metabolic disorders, genetic mutations affecting protein quality control pathways (such as mutations in the Parkin, PINK1, or ATG genes), polypharmacy, and exposure to high doses or prolonged courses of proteostasis-disrupting drugs. Concomitant environmental stresses, such as hypoxia or oxidative stress, can synergistically exacerbate proteostasis collapse in predisposed individuals.

Clinical Features

The clinical manifestations of drug-induced proteostasis collapse are diverse and often organ-specific. Neurological features may include cognitive dysfunction, ataxia, myopathy, or peripheral neuropathy. Hepatic involvement can present as transaminitis or steatohepatitis, while renal manifestations may include proteinuria or acute kidney injury. In severe cases, multi-organ dysfunction may ensue. The temporal relationship between drug exposure and symptom onset, as well as the reversibility of symptoms upon drug withdrawal, are important diagnostic clues.

Diagnosis

Diagnosis is primarily clinical, supported by laboratory and histopathological findings. Biomarkers of ER stress (e.g., GRP78, CHOP), proteasomal activity assays, and detection of protein aggregates in tissue biopsies can provide mechanistic insights. Imaging modalities such as MRI may reveal organ-specific sequelae, such as leukoencephalopathy. Exclusion of alternative etiologies and careful medication reconciliation are essential components of the diagnostic process. Genetic screening for mutations affecting proteostasis pathways may be warranted in recurrent or familial cases.

Treatment & Management

The cornerstone of management is prompt identification and discontinuation of the offending agent. Supportive therapy is tailored to the affected organ system and severity of presentation. Pharmacological chaperones (e.g., tafamidis for transthyretin amyloidosis), proteasome activators, and agents that enhance autophagy (e.g., rapamycin) have been explored in select cases. Antioxidant therapy may have adjunctive benefits in mitigating oxidative proteostatic stress. Multidisciplinary care involving pharmacists, neurologists, and other specialists is often required for optimal management.

Recent Advances / Emerging Therapies

Recent advances emphasize the development of small molecules that selectively modulate proteostasis pathways. Proteostasis regulators, such as heat shock protein inducers and chemical chaperones, are under active investigation. Gene editing technologies targeting proteostasis-related genes offer future therapeutic promise. High-throughput screening for drug-proteome interactions, coupled with systems biology approaches, is improving our understanding of off-target drug effects and facilitating personalized risk assessment. Ongoing clinical trials are evaluating the efficacy of novel autophagy enhancers and proteasome modulators in mitigating drug-induced proteostasis collapse.

Guideline Recommendations

Current guidelines advocate for routine assessment of proteostasis risks in patients receiving known high-risk drugs, particularly in those with baseline vulnerabilities. Dose adjustments, careful monitoring for early signs of toxicity, and the use of less disruptive alternatives when feasible are recommended. Interdisciplinary collaboration and patient education regarding potential symptoms are essential components of preventive strategies. Guideline updates are anticipated as new biomarkers and therapeutic agents become clinically available.

Conclusion

Drug-induced proteostasis collapse represents a significant and clinically relevant complication of pharmacotherapy, with far-reaching implications for patient safety and outcomes. Advances in mechanistic understanding, diagnostic biomarkers, and targeted therapies hold promise for improved prevention, recognition, and management of this condition. Ongoing research and adherence to emerging clinical guidelines are crucial for minimizing the burden of drug-induced proteostasis disorders in contemporary medical practice.